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We developed a method for applying HIV-1 DNA
vaccine topically in mice. Topical application of
DNA vaccine to the skin is useful against infections.
To ®nd a less expensive and less cumbersome vac-
cination method, we administered HIV-1 DNA vac-
cine to the skin of mice after elimination of
keratinocytes using a fast-acting adhesive. HIV-1
DNA vaccine induced high levels of both humoral
and cell-mediated immune activity against HIV-1
envelope antigen. A high level of HIV-1-speci®c
cytotoxic T lymphocyte response was also observed,
and a high level of IFN-g and IL-4 production was
induced by the improved skin application of DNA
vaccine. High levels of both HIV-speci®c cytotoxic
T lymphocyte and delayed type hypersensitivity in
topical application were induced by coadministration
of the DNA vaccine with IL-12 expression plasmids
and granulocyte-macrophage colony-stimulating fac-
tor expression plasmids. These immune responses
were inhibited by intradermal injection of anti-
CD11c or anti-I-A/I-E antibody. Therefore, topical
administration of DNA vaccine is an effective route,
and may be very useful for the prevention of infec-
tious diseases. Key words: adjuvant/topical application/
vaccination. Journal of Investigative Dermatology
Symposium Proceedings 6:76±80, 2001
T
he induction of a strong and long-lasting immunity
is one of the most important elements in develop-
ing an effective human immunode®ciency virus
(HIV) vaccine. Vaccines have been used to over-
come many dangerous infections. Standard vaccines,
such as live vaccines, attenuated live vaccines, and killed
vaccines, vary in the kind and duration of security they provide.
DNA vaccines have the advantage of inducing the production
of protein antigens from DNA in host cells that exhibit natural
glycosylation and processing, as is seen with the use of live
attenuated vaccines (Hassett and Whitton, 1996; Donnelly et al,
1997; Ishii et al, 1997a; Weiner and Kennedy, 1999).
We have been developing an HIV-1-speci®c DNA vaccine
candidate that is constructed from HIV-1 env and rev genes.
DNA vaccine for HIV-1 has now been proved to induce high
levels of both humoral and cell-mediated immune responses.
We have previously reported (Okada et al, 1997; Toda et al,
1997; Tsuji et al, 1997a, b; Sasaki et al, 1998) that DNA
vaccine induces strong cell-mediated immune responses, namely,
cytotoxic T lymphocyte (CTL) response, delayed type hyper-
sensitivity (DTH) response, and T cell proliferation response.
We have recently demonstrated how the immunogenicity of
DNA vaccine varies depending on the route of immunization
in mice (Okada et al, 1997; Toda et al, 1997; Tsuji et al, 1997a,
b; Sasaki et al, 1998; Xin et al, 1998; Liu et al, in press). The
vaccines usually are derived by injection, commonly into
muscle, which puts genes directly into cells and also leads to
uptake by cells in the vicinity of the inserted needle. But in
developing countries, simpler devices than needles are necessary.
In this review, we demonstrate the immunologic and
characteristic importance of DNA vaccine. The mechanism of
improved topical application of DNA vaccine to induce
immune response is also discussed.
CHARACTERISTICS OF DNA VACCINE AND
CYTOKINE EXPRESSION PLASMID
The immunogenic DNA plasmids, pCMV160IIIB which
encodes glycoprotein 160 (gp160) of HIV-1 IIIB and pcREV
which encodes HIV-1 REV (hereafter referred to as IIIB/
REV), were described in our previous report (Okuda et al,
1995). Although our DNA vaccine formulation was designed to
elicit an env-speci®c immune response, the rev expression
plasmids were included because the expression of env protein
is dependent on rev coexpression (Okuda et al, 1995) (Fig 1).
Mouse IL-12 expression plasmid, designated pCAGGS IL-12,
was previously described (Okada et al, 1997). Both mouse IL-12
p35 and p40 cDNA were inserted into the EcoRI site of the
same pCAGGS expression vector (pIL-12). The mouse GM-
CSF expression plasmid, designated pCAGGS GM-CSF (pGM-
CSF), was provided by Dr. M. L. Disis, University of
Washington, Seattle, WA (Disis et al, 1996).
IMMUNOGENICITY OF VARIOUS ROUTES OF
IMMUNIZATION
We applied three different immunization methods, intramuscular
(i.m.), intranasal (i.n.), and topical application. The detailed
methods of i.m. (Okuda et al, 1995) and i.n. (Okada et al,
1997) immunization were described previously. Topical appli-
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cation was conducted as follows. All hairs of an area on the
back of a mouse were pulled out and the area was disinfected
with 70% ethanol. Next, strong fast-acting adhesive (Alon Alfa,
TOA, Tokyo, Japan) was smeared on a glass slide to cover
approximately 0.5 cm2 and stuck to the back of the mouse near
the rump. After an interval of 20±30 s, the slide was ripped off
so that the keratinous layer of the skin was removed with it. A
solution of DNA-expressing plasmids dissolved in 20±30 ml of
saline was applied to the newly exposed skin region to achieve
immunization. This procedure was performed on days 0, 7, and
14 of the experiment (Liu et al in press). The immune response
induced by DNA vaccine differed according to the route of
immunization (i.m., i.n., or topical). As shown in Fig 2, topical
application without stripping the skin induced weak antibody
response or weak DTH response, even though 100 mg of DNA
vaccine was applied (Liu et al, in press); however, topical
application of DNA vaccine to the skin with stripping was a
useful route of immunization against HIV. It induced strong
HIV-1-speci®c immune response, and remained detectable after
3 mo in all immunization methods. We demonstrated that
strong fast-acting adhesive adhesive (Alon Alfa) successfully
removed the keratinocytic layers to uncover potently antigenic
dendritic cells near the skin surface. Although it would not be
the best way to obtain the same condition in clinical use, it is
of great importance in the sense that it shows how DNA
vaccine becomes very effective via topical application if the
keratinocytic layer is removed. Other methods can be used to
remove the layer, such as multiple application of adhesive tape
in combination with a low concentration of SDS and/or urea
cream, or a gene gun. Human skin has 7±10 keratinocytic
layers on the epidermis, whereas mouse skin has only two to
four layers. It would be more dif®cult for DNA plasmids to be
taken up by dendritic cells or Langerhans cells without stripping
off several layers in humans
ADJUVANT EFFECT
An adjuvant is one of the most important elements in developing an
effective HIV vaccine. The use of liposomes may be helpful in this
regard, because they are reportedly effective for enhancing
immunization (Yasuda et al, 1977) and for introducing substances
into cells (Flegner et al, 1996). Positively charged cationic liposomes
were also shown to introduce genes into cells by forming
complexes with DNA (Rose et al, 1991). A detailed method for
cationic liposome preparation has been reported previously (Ishii et
al, 1997b). As shown in Fig 2, the inoculation of DNA vaccine
with liposomes induced a substantial DTH reaction. Compared
with DNA vaccine plus cationic liposome, topical administration of
only the DNA vaccine resulted in weaker DTH response. DNA
vaccine plus cationic liposome also induced higher levels of
antibody production than DNA vaccine alone. The HIV-1-speci®c
CTL activity was stronger when the DNA vaccine and cationic
liposome combination was used. These results showed that cationic
liposomes can be highly effective when used with DNA vaccines.
Therefore, DNA vaccination with liposomes can induce strong
humoral and cell-mediated immune responses.
EFFECT OF IMMUNOMODULATORY MOLECULES:
IL-12 AND GM-CSF
To examine the effects of cytokine-expression plasmid on DNA
vaccine, pIL-12 and/or pGM-CSF were coimmunized with
DNA vaccine (Liu et al, in press). When DNA vaccine was
applied in combination with pIL-12 and/or pGM-CSF, DTH
was signi®cantly enhanced as compared with application of
DNA vaccine alone (Fig 3). Coadministration of DNA vaccine
with pIL-12 and/or pGM-CSF induced a stronger CTL
response and higher titer of HIV-1-speci®c serum IgG and
IgA antibodies, when compared with DNA vaccine alone.
These results demonstrated that improved topical application of
HIV-1 DNA vaccine with pIL-12 and pGM-CSF could induce
a signi®cant level both of cell-mediated immune response
(DTH and CTL) and of antibody production.
TH1 AND TH2
We studied the pro®le of cytokines activated with DNA
vaccine alone or with pIL-12 and/or pGM-CSF by topical
application. As shown in Fig 4, a signi®cant increase in IFN-g
and IL-4 production was observed in mice with the use of
DNA vaccine. The increase in IL-4 production was greater
than that of IFN-g when topical application rather than i.m.
immunization was used. These results suggest that topical
application of DNA vaccine preferentially activates Th2
cytokine production in comparison with i.m. immunization.
This study demonstrated that strong HIV-1-speci®c immune
response was induced by topical application. In humoral
response, IgG was the most prominently induced. Moreover,
this humoral response was enhanced by coimmunization with
the plasmid encoding GM-CSF. But in the IgG subclass, the
IgG1/IgG2a ratio of topical application was higher than that of
i.m. immunization. Cellular immunity, as represented by DTH
and CTL, was also enhanced by coapplication of IL-12-
expressing plasmid. We detected high levels of IL-4 production
and substantial levels of IFN-g in the culture supernatant of
splenocytes with antigens. Taken together, the topical applica-
tion of DNA vaccine seems to induce both Th2 and Th1, but
predominantly Th2 rather than Th1 cytokine response. We
need to resolve the problem of variation in Th1±Th2
interaction caused by different immunization routes.
IMPORTANCE OF LANGERHANS CELLS
The effect of anti-CD11c antibody on skin-mediated immune
responses was analyzed, and both DTH (footpad swelling) and
antibody response (IgG) were assayed. As shown in Fig 5, the
immune response was signi®cantly inhibited by the injection of
anti-CD11c monoclonal antibody or anti-I-Ad/I-Ed monoclonal
antibody (Liu et al, in press). It suggests that the immune
response induced by topical application to the skin is mediated
by the I-A/I-E and/or CD11c positive cells, presumably
Figure 1. A gp160-expressing plasmid driving the CMV
promoter. (A) Gene organization in the env region fragment (base
position 5496±8474; Okuda et al, 1995) inserted into the expression
plasmid. (B) Plasmid construction.
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Langerhans cells in the epidermis and dermis. Robinson et al
(1999) reported that strong immune response induced by
intradermal injection of DNA vaccine indicated the importance
of Langerhans cells in the dermis. We agree with Robinsons'
hypothesis (1999), and understand the need to analyze
Langerhans cells in the epidermis and dermis.
Figure 2. Comparison of immune responses
using three routes of immunization. On days
0, 7, and 14, 5±6 BALB/C mice were immunized
i.n., i.m., or topically (t.a.) with the indicated
volume of IIIB/REV DNA vaccine. Serum IgG
and DTH (footpad swelling) response were
assayed after 7 d and 3 mo. Similar results were
obtained in two other separate experiments.
*p < 0.01 versus nonimmune controls (saline
application); ²p < 0.05 between topical application
with stripping and without stripping.
Figure 3. Footpad swelling response in mice
induced by topical application of DNA
vaccine with or without IL-12, GM-CSF
expression plasmids. BALB/C mice were
treated three times with 30 mg DNA vaccine
alone or with 10 mg pIL-12 and/or pGM-CSF.
Seven days after vaccination, the footpad-swelling
assay was carried out. The response of each group
represents the mean 6 SE of 5±6 mice. *p < 0.05
versus pCMV empty and/or pCAGGS empty
groups; ²p < 0.05 versus DNA vaccine only
groups. Similar results were obtained in two other
separate experiments.
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CONCLUSION
The classical or genetic vaccination methods that use needles or
various infectious vector systems suffer from problems of admin-
istration expense and patient compliance. In this study we
demonstrated that application of DNA vaccine to animal skin
induced both cellular and humoral immune response against HIV
envelope protein. We previously reported several delivery systems
for DNA vaccine (Bukawa et al, 1995; Okuda et al, 1995; Okada et
al, 1997; Toda et al, 1997; Tsuji et al, 1997a, b; Sasaki et al, 1998),
including i.m. and i.n. administration to induce immune response
against HIV protein. Immunization including subcutaneous or
intradermal immunization has been widely studied (Hengge et al,
1996; Sato et al, 1996; Tan et al, 1996; Tutin et al, 1999). Topical
application tends to be more potent in inducing both humoral and
cellular immune response, and it requires no invasive maneuvers
such as needle injection in developing countries. Therefore, this
route is potentially useful for immunization against HIV. We also
applied our DNA vaccine without removing hair or keratinocytes
(Fan et al, 1999), but these methods did not work. We need to try
some more convenient topical application system. The gene gun
propels plasmids into cells near the surface of the body, typically
those of the skin or mucous membranes (Weiner and Kennedy,
1999). In addition, adjuvant-like cationic liposomes, or immuno-
modulatory molecules such as GM-CSF and IL-12 expression
plasmids, were proven to greatly modify the immune response by
topical coadministration. These effects of cytokine expressing
plasmids were able to ef®ciently improve the vaccination effect.
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